Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| KIF5B-driven unfolded protein response reprograms breast cancer immunosuppressive microenvironment for single-cell guided therapeutic targeting. | Discov Oncol | 2026 | 41587002 | PubTator, text mining | PubMed |
| Actionable driver gene alterations in early-stage non-small cell lung cancer: a review. | Ther Adv Med Oncol | 2026 | 41555859 | PubTator, text mining | PubMed |
| Structural analysis of a motor with increased mechanical output reveals new transitions in kinesin microtubule motility. | Sci Rep | 2026 | 41491787 | PubTator, text mining | PubMed |
| Selpercatinib-induced Acalculous Cholecystitis in an Elderly Patient with RET Fusion-positive Non-small Cell Lung Cancer. | Intern Med | 2026 | 41297948 | PubTator, text mining | PubMed |
| An unusual spindle cell variant of papillary thyroid carcinoma with KIF5B::MET fusion: report of a case. | Virchows Arch | 2026 | 40924136 | PubTator, text mining | PubMed |
| Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review. | Front Oncol | 2025 | 41675516 | PubTator, text mining | PubMed |
| Tumor Lysis Syndrome Induced by Selpercatinib in Rearranged During Transfection (RET) Fusion-Positive Non-Small-Cell Lung Cancer. | Cureus | 2025 | 41477385 | PubTator, text mining | PubMed |
| Molecular motors orchestrate pause-and-run dynamics to facilitate intracellular transport. | bioRxiv | 2025 | 41357985 | PubTator, text mining | PubMed |
| Cortical morphometric similarity patterns and molecular signatures across ischemic stroke recovery. | Front Neurol | 2025 | 41356252 | PubTator, text mining | PubMed |
| Dominant spinal muscular atrophy linked mutations in the cargo binding domain of BICD2 result in altered interactomes and dynein hyperactivity. | Elife | 2025 | 41334889 | PubTator, text mining | PubMed |
| Identification of immunogenic KIF5B-RET fusion neopeptides driving immune stimulation in tumor specific CD8+ T cells. | Front Immunol | 2025 | 41246330 | PubTator, text mining | PubMed |
| BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models. | Front Pharmacol | 2025 | 41181595 | PubTator, text mining | PubMed |
| Human OPN-derived peptide SV prevents BPD model through interacting with KIF5B to repair mitochondrial damage and inhibit apoptosis. | iScience | 2025 | 41158864 | PubTator, text mining | PubMed |
| Kinesin-1 coordinates cross-talk between microtubule and actin cytoskeletons during dendritic cell migration. | Sci Adv | 2025 | 41105759 | PubTator, text mining | PubMed |
| Kinesin superfamily proteins in cancer: unveiling their role in chemotherapy. | Int Immunopharmacol | 2025 | 41016201 | PubTator, text mining | PubMed |
| Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer: A Real-World Cohort Study in Finland. | Cancer Med | 2025 | 41015991 | PubTator, text mining | PubMed |
| Clinicogenomic and treatment outcomes in RET fusion-positive NSCLC: A multicenter study in Latin American Hispanic patients. | Cancer Treat Res Commun | 2025 | 41005103 | PubTator, text mining | PubMed |
| JIP4 and RILPL1 utilize opposing motor force to dynamically regulate lysosomal tubulation. | J Cell Biol | 2025 | 40990465 | PubTator, text mining | PubMed |
| Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold. | J Med Chem | 2025 | 40920215 | PubTator, text mining | PubMed |
| Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transduction. | Life Sci Alliance | 2025 | 40897470 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=3